|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SCRIB |
Gene summary for SCRIB |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SCRIB | Gene ID | 23513 |
| Gene name | scribble planar cell polarity protein | |
| Gene Alias | CRIB1 | |
| Cytomap | 8q24.3 | |
| Gene Type | protein-coding | GO ID | GO:0000278 | UniProtAcc | A0A0G2JNZ2 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 23513 | SCRIB | HTA11_347_2000001011 | Human | Colorectum | AD | 6.66e-06 | 2.04e-01 | -0.1954 |
| 23513 | SCRIB | HTA11_696_2000001011 | Human | Colorectum | AD | 1.16e-03 | 2.10e-01 | -0.1464 |
| 23513 | SCRIB | HTA11_1391_2000001011 | Human | Colorectum | AD | 2.43e-05 | 3.45e-01 | -0.059 |
| 23513 | SCRIB | HTA11_866_3004761011 | Human | Colorectum | AD | 1.65e-02 | 1.64e-01 | 0.096 |
| 23513 | SCRIB | HTA11_7696_3000711011 | Human | Colorectum | AD | 2.94e-09 | 3.23e-01 | 0.0674 |
| 23513 | SCRIB | HTA11_99999971662_82457 | Human | Colorectum | MSS | 2.84e-16 | 5.62e-01 | 0.3859 |
| 23513 | SCRIB | HTA11_99999974143_84620 | Human | Colorectum | MSS | 1.59e-18 | 5.61e-01 | 0.3005 |
| 23513 | SCRIB | LZE20T | Human | Esophagus | ESCC | 1.82e-07 | 2.63e-01 | 0.0662 |
| 23513 | SCRIB | LZE24T | Human | Esophagus | ESCC | 1.78e-07 | 1.84e-01 | 0.0596 |
| 23513 | SCRIB | P1T-E | Human | Esophagus | ESCC | 2.56e-10 | 3.47e-01 | 0.0875 |
| 23513 | SCRIB | P2T-E | Human | Esophagus | ESCC | 1.68e-07 | 1.17e-01 | 0.1177 |
| 23513 | SCRIB | P4T-E | Human | Esophagus | ESCC | 6.05e-09 | 6.09e-02 | 0.1323 |
| 23513 | SCRIB | P5T-E | Human | Esophagus | ESCC | 8.21e-12 | 1.29e-01 | 0.1327 |
| 23513 | SCRIB | P8T-E | Human | Esophagus | ESCC | 4.57e-14 | 2.27e-01 | 0.0889 |
| 23513 | SCRIB | P9T-E | Human | Esophagus | ESCC | 1.43e-13 | 1.97e-01 | 0.1131 |
| 23513 | SCRIB | P10T-E | Human | Esophagus | ESCC | 7.44e-08 | 1.04e-01 | 0.116 |
| 23513 | SCRIB | P12T-E | Human | Esophagus | ESCC | 1.26e-11 | 2.23e-01 | 0.1122 |
| 23513 | SCRIB | P15T-E | Human | Esophagus | ESCC | 2.11e-15 | 2.88e-01 | 0.1149 |
| 23513 | SCRIB | P16T-E | Human | Esophagus | ESCC | 6.31e-09 | 2.38e-01 | 0.1153 |
| 23513 | SCRIB | P17T-E | Human | Esophagus | ESCC | 2.21e-08 | 2.16e-01 | 0.1278 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:005165021 | Liver | HCC | establishment of vesicle localization | 103/7958 | 161/18723 | 2.94e-08 | 6.69e-07 | 103 |
| GO:00315031 | Liver | HCC | protein-containing complex localization | 129/7958 | 220/18723 | 9.38e-07 | 1.42e-05 | 129 |
| GO:005164821 | Liver | HCC | vesicle localization | 107/7958 | 177/18723 | 1.05e-06 | 1.57e-05 | 107 |
| GO:000690311 | Liver | HCC | vesicle targeting | 34/7958 | 45/18723 | 6.75e-06 | 8.08e-05 | 34 |
| GO:0045786 | Liver | HCC | negative regulation of cell cycle | 204/7958 | 385/18723 | 1.84e-05 | 1.99e-04 | 204 |
| GO:006195111 | Liver | HCC | establishment of protein localization to plasma membrane | 41/7958 | 60/18723 | 4.65e-05 | 4.49e-04 | 41 |
| GO:004311221 | Liver | HCC | receptor metabolic process | 96/7958 | 166/18723 | 4.69e-05 | 4.50e-04 | 96 |
| GO:0045930 | Liver | HCC | negative regulation of mitotic cell cycle | 130/7958 | 235/18723 | 4.69e-05 | 4.50e-04 | 130 |
| GO:00324562 | Liver | HCC | endocytic recycling | 48/7958 | 73/18723 | 5.07e-05 | 4.83e-04 | 48 |
| GO:004206022 | Liver | HCC | wound healing | 219/7958 | 422/18723 | 5.34e-05 | 5.04e-04 | 219 |
| GO:000689821 | Liver | HCC | receptor-mediated endocytosis | 134/7958 | 244/18723 | 5.73e-05 | 5.31e-04 | 134 |
| GO:003010021 | Liver | HCC | regulation of endocytosis | 117/7958 | 211/18723 | 9.56e-05 | 8.32e-04 | 117 |
| GO:00018415 | Liver | HCC | neural tube formation | 62/7958 | 102/18723 | 1.47e-04 | 1.18e-03 | 62 |
| GO:003001022 | Liver | HCC | establishment of cell polarity | 82/7958 | 143/18723 | 2.38e-04 | 1.79e-03 | 82 |
| GO:00360103 | Liver | HCC | protein localization to endosome | 19/7958 | 24/18723 | 2.80e-04 | 2.02e-03 | 19 |
| GO:015010511 | Liver | HCC | protein localization to cell-cell junction | 17/7958 | 21/18723 | 3.71e-04 | 2.56e-03 | 17 |
| GO:00018433 | Liver | HCC | neural tube closure | 53/7958 | 88/18723 | 5.95e-04 | 3.75e-03 | 53 |
| GO:00140204 | Liver | HCC | primary neural tube formation | 56/7958 | 94/18723 | 6.19e-04 | 3.86e-03 | 56 |
| GO:00606063 | Liver | HCC | tube closure | 53/7958 | 89/18723 | 8.67e-04 | 5.14e-03 | 53 |
| GO:00308795 | Liver | HCC | mammary gland development | 75/7958 | 137/18723 | 2.52e-03 | 1.22e-02 | 75 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa04530 | Colorectum | AD | Tight junction | 76/2092 | 169/8465 | 5.49e-09 | 9.69e-08 | 6.18e-08 | 76 |
| hsa045301 | Colorectum | AD | Tight junction | 76/2092 | 169/8465 | 5.49e-09 | 9.69e-08 | 6.18e-08 | 76 |
| hsa045304 | Colorectum | MSS | Tight junction | 66/1875 | 169/8465 | 4.10e-07 | 6.25e-06 | 3.83e-06 | 66 |
| hsa04390 | Colorectum | MSS | Hippo signaling pathway | 48/1875 | 157/8465 | 8.32e-03 | 3.10e-02 | 1.90e-02 | 48 |
| hsa045305 | Colorectum | MSS | Tight junction | 66/1875 | 169/8465 | 4.10e-07 | 6.25e-06 | 3.83e-06 | 66 |
| hsa043901 | Colorectum | MSS | Hippo signaling pathway | 48/1875 | 157/8465 | 8.32e-03 | 3.10e-02 | 1.90e-02 | 48 |
| hsa0516510 | Esophagus | ESCC | Human papillomavirus infection | 215/4205 | 331/8465 | 7.86e-09 | 7.12e-08 | 3.65e-08 | 215 |
| hsa0520325 | Esophagus | ESCC | Viral carcinogenesis | 137/4205 | 204/8465 | 2.47e-07 | 1.88e-06 | 9.62e-07 | 137 |
| hsa04530211 | Esophagus | ESCC | Tight junction | 105/4205 | 169/8465 | 6.73e-04 | 2.23e-03 | 1.14e-03 | 105 |
| hsa0439018 | Esophagus | ESCC | Hippo signaling pathway | 92/4205 | 157/8465 | 1.46e-02 | 3.31e-02 | 1.69e-02 | 92 |
| hsa0516515 | Esophagus | ESCC | Human papillomavirus infection | 215/4205 | 331/8465 | 7.86e-09 | 7.12e-08 | 3.65e-08 | 215 |
| hsa0520335 | Esophagus | ESCC | Viral carcinogenesis | 137/4205 | 204/8465 | 2.47e-07 | 1.88e-06 | 9.62e-07 | 137 |
| hsa04530310 | Esophagus | ESCC | Tight junction | 105/4205 | 169/8465 | 6.73e-04 | 2.23e-03 | 1.14e-03 | 105 |
| hsa0439019 | Esophagus | ESCC | Hippo signaling pathway | 92/4205 | 157/8465 | 1.46e-02 | 3.31e-02 | 1.69e-02 | 92 |
| hsa0453042 | Liver | HCC | Tight junction | 110/4020 | 169/8465 | 2.45e-06 | 2.28e-05 | 1.27e-05 | 110 |
| hsa051652 | Liver | HCC | Human papillomavirus infection | 188/4020 | 331/8465 | 3.34e-04 | 1.49e-03 | 8.29e-04 | 188 |
| hsa052032 | Liver | HCC | Viral carcinogenesis | 117/4020 | 204/8465 | 2.68e-03 | 8.98e-03 | 5.00e-03 | 117 |
| hsa0453052 | Liver | HCC | Tight junction | 110/4020 | 169/8465 | 2.45e-06 | 2.28e-05 | 1.27e-05 | 110 |
| hsa051653 | Liver | HCC | Human papillomavirus infection | 188/4020 | 331/8465 | 3.34e-04 | 1.49e-03 | 8.29e-04 | 188 |
| hsa052033 | Liver | HCC | Viral carcinogenesis | 117/4020 | 204/8465 | 2.68e-03 | 8.98e-03 | 5.00e-03 | 117 |
| Page: 1 2 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SCRIB | SNV | Missense_Mutation | rs781807477 | c.3196G>A | p.Val1066Met | p.V1066M | Q14160 | protein_coding | tolerated(0.15) | benign(0.235) | TCGA-A7-A3IY-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD |
| SCRIB | SNV | Missense_Mutation | novel | c.1576N>G | p.Pro526Ala | p.P526A | Q14160 | protein_coding | tolerated(0.83) | benign(0.003) | TCGA-A7-A6VY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | CR |
| SCRIB | SNV | Missense_Mutation | c.1987N>C | p.Glu663Gln | p.E663Q | Q14160 | protein_coding | tolerated(0.07) | possibly_damaging(0.662) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| SCRIB | SNV | Missense_Mutation | rs782366459 | c.4831G>A | p.Glu1611Lys | p.E1611K | Q14160 | protein_coding | deleterious_low_confidence(0.03) | benign(0.197) | TCGA-AC-A2BK-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | cytoxan | CR |
| SCRIB | SNV | Missense_Mutation | novel | c.3743A>C | p.His1248Pro | p.H1248P | Q14160 | protein_coding | tolerated(0.38) | benign(0) | TCGA-BH-A0BT-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
| SCRIB | SNV | Missense_Mutation | rs781995997 | c.3296G>A | p.Arg1099Gln | p.R1099Q | Q14160 | protein_coding | tolerated(1) | benign(0.042) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| SCRIB | deletion | Frame_Shift_Del | novel | c.2039delN | p.Asn680ThrfsTer37 | p.N680Tfs*37 | Q14160 | protein_coding | TCGA-D8-A1XQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| SCRIB | SNV | Missense_Mutation | novel | c.2794N>A | p.Val932Ile | p.V932I | Q14160 | protein_coding | deleterious(0.02) | probably_damaging(0.999) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| SCRIB | SNV | Missense_Mutation | novel | c.1448N>C | p.Val483Ala | p.V483A | Q14160 | protein_coding | tolerated(0.3) | benign(0.035) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| SCRIB | SNV | Missense_Mutation | rs369876190 | c.4444N>A | p.Glu1482Lys | p.E1482K | Q14160 | protein_coding | deleterious(0.03) | possibly_damaging(0.461) | TCGA-C5-A1BQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |